Business Wire

Aviceda Announces FDA Clearance of the Investigational New Drug (IND) Application for AVD-104, a Novel Glyco-Mimetic Nanoparticle, Enabling Initiation of Phase 2 Clinical Trials for the Treatment of Geographic Atrophy from Macular Degeneration


Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by harnessing the power of glycobiology to modulate the innate immune system and alleviate chronic, non-resolving inflammation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for AVD-104, enabling the company to proceed with initiating Phase 2 clinical trials of its lead intravitreal ocular asset for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The Phase 2 SIGLEC trial is expected to begin in Q2 2023.

“The FDA’s acceptance of our IND application to initiate the clinical evaluation of AVD-104 brings us one step closer to introducing a potentially paradigm-shifting treatment for people living with geographic atrophy and macular degeneration,” said Mohamed Genead, M.D., Aviceda’s Co-Founder, President & Chief Executive Officer. “The AVD-104 IND clearance marks an important milestone for Aviceda as we continue our track record of execution as the leader in the glycome field. We are thrilled to advance the development of AVD-104 in the U.S. and are working to rapidly enroll patients in the Phase 2 portion of the study. We look forward to presenting additional data later this year.”

AVD-104 is an intravitreal nanoparticle molecule with a unique dual mechanism of action for the treatment of GA through its modulation of critical inflammatory pathways via inhibition of the activity of retinal macrophages and repolarization of activated macrophages to their resolution state coupled with inhibition of complement cascade amplification.

“I am very excited to bring the power of our glyco-biology based technology platform to address the significant unmet medical needs in patients with macular degeneration. As a practicing vitreoretinal specialist, I saw firsthand the devastating effect of this disease on my patients. This is the first step in bringing a novel and differentiated therapy to these patients,” said David Callanan, M.D., Chief Medical Officer of Aviceda.

About AMD

Age-related macular degeneration (AMD) is a major cause of moderate and severe vision loss in adults over 60 worldwide, currently affecting approximately 11 million people in the United States. Central vision can be prominently, and permanently, reduced such that affected patients can lose their independence and become limited in many basic functions including reading, driving, and recognizing faces. The wet, or neovascular, form of AMD occurs because of abnormal blood vessel growth, bleeding, and scarring that destroys central retinal cells. Approved anti-VEGF therapies have helped control and treat this form. The dry, or non-neovascular, form of AMD is characterized by the development of geographic atrophy (GA) in which there is irreversible progressive destruction of central retinal cells and underlying blood vessels due to chronic inflammation (with over-activated macrophage activity with resultant phagocytosis of retinal and RPE cells) and abnormal complement activation in the retinal photoreceptor, retinal pigment epithelial, and choriocapillaris regions in the back of the eye. Current therapeutics are under development to treat dry AMD by reducing chronic inflammation and inhibiting elements of the complement cascade.

About Aviceda Therapeutics and AVD-104

Aviceda is a private clinical-stage biotechnology company located in Cambridge, MA with a proprietary nano-technology HALOS™ platform and an IND-cleared ophthalmic lead product for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). AVD-104 is an intravitreal nanoparticle molecule with a unique dual mechanism of action for the treatment of GA through its modulation of critical inflammatory pathways: 1) Direct inhibition of the activity of damaging phagocytic macrophages and repolarization of activated macrophages to their resolution state, and 2) Inhibition of complement cascade amplification. AVD-104 has demonstrated robust in-vitro/vivo efficacy with inhibition of both inflammatory & complement pathways and the potential for every 4-6-month dosing. Outstanding safety has been demonstrated in multiple animal models, including non-human primates, in which no signs of intra-ocular inflammation were seen. In addition, AVD-104 has demonstrated anti-neovascular activity equivalent to that of aflibercept (Eylea) in a well-established ocular CNV model. Phase 2 clinical trial is expected to begin in Q2 of 2023.

Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas including neurology, oncology, fibrosis, and immunology.

Learn more about Aviceda Therapeutics.

To view this piece of content from, please give your consent at the top of this page.

Contact information

For Investor Relations and Media:

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Protectoria Venture Signs Agreement to Propose a Decentralised Digital ID to Indonesia.7.6.2023 09:00:00 EEST | Press release

Protectoria Venture AS, , has together with its local partner, PT Gimle Investment Group, signed an agreement with PT INTI (Persero), the state-owned enterprise acting as a strategic trusted adviser to the central government, on proposing a decentralised digital identity infrastructure services for public entities, companies, and citizens in Indonesia. This press release features multimedia. View the full release here: Foto: Protectoria The companies commit to cooperate exclusively to design, build and operate a digital decentralised identity infrastructure that can be offered towards any service provider from any sector or industry in a national roll-out. Citizens will be able to control their own data and have easy and secure access to all types of digital services in society. Protectoria Venture will provide the decentralised digital identity services based on the firm´s technology platform with archi

Hillstone Networks named a Customers’ Choice in the 2023 Gartner Peer Insights™ Voice of the Customer for Network Firewalls7.6.2023 09:00:00 EEST | Press release

Hillstone Networks, a leading provider of cybersecurity solutions, announced today that it has been included in two Gartner Peer Insights “Voice of the Customer” reports Hillstone has been recognized as a Customers' Choice vendor for Network Firewalls and named a Strong Performer for its newly released Network Detection and Resolution (NDR) solution. Gartner Peer Insights Customers' Choice distinctions are based on voluntary and verified feedback and ratings from end-user professionals who have experience purchasing, implementing, or using the products or services. “Customers have spoken and recognized our unwavering commitment to providing integrative cybersecurity solutions that have effectively delivered coverage, control, and consolidation to over 26,000 of their peers globally, in a challenging and dynamic cybersecurity landscape,” said Tim Liu, co-founder & CTO, of Hillstone Networks. “We will continue to innovate and push the boundaries of cybersecurity to protect our customers'

ReNew Announces Results for the Fourth Quarter (Q4 FY23) and Fiscal 2023, both ended March 31, 20237.6.2023 00:00:00 EEST | Press release

ReNew Energy Global Plc (“ReNew” or “the Company”) (Nasdaq: RNW, RNWWW), a leading decarbonization solutions company, today announced its consolidated IFRS results for Q4 FY23 and the fiscal year ended March 31, 2023. Operating Highlights: As of March 31, 2023, the Company’s portfolio consisted of 13.7 GWs, a 28.2% increase year on year, of which ~ 8.0 GWs are commissioned and 5.7 GWs are committed. 101 MW of Purchase Power Agreements (“PPAs”) were signed in the fourth fiscal quarter of 2023 and only ~1% of our total portfolio have Letters of Award that await a PPA. Total Income (or total revenue) for Q4 FY23 was INR 25,916 million (US$ 315 million), an increase of 47.1% over Q4 FY22. Adjusted EBITDA(2) for Q4 FY23 was INR 12,010 million (US$ 146 million), as against INR 12,787 million (US$ 156 million) in Q4 FY22. Net profit for Q4 FY23 was INR 74 million (US$ 1 million) compared to a net loss of INR 3,554 million (US$ 43 million) for Q4 FY22. Cash Flow to equity(2)(“CFe”) for Q4 was

Kenvue to Announce Second Quarter 2023 Results on July 20, 20236.6.2023 23:30:00 EEST | Press release

Kenvue Inc. (NYSE: KVUE) (“Kenvue”), the world’s largest pure-play consumer health company by revenue, today announced that its financial results for the second quarter ending July 2, 2023, will be released before market open on July 20, 2023. The company will host a conference call and webcast at 7:30 a.m. Eastern Time to report its second quarter results. The conference call can be accessed by dialing 877-407-8835 from the U.S. or 201-689-8779 from international locations. A live webcast of the conference call will be available at A replay will be available approximately two hours after the live event. About Kenvue Kenvue is the world’s largest pure-play consumer health company by revenue. Built on more than a century of heritage and propelled forward by science, our iconic brands—including AVEENO®, BAND-AID® Brand Adhesive Bandages, JOHNSON’S®, LISTERINE®, NEUTROGENA®, TYLENOL® and ZYRTEC® — are recommended by health care professionals and can be truste

Bentley Systems Announces Allen Li has Joined as General Manager, China6.6.2023 23:01:00 EEST | Press release

Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced that Allen Li has been appointed to the new role of General Manager, China, reporting to Chief Revenue Officer Brock Ballard. Allen Li has had a long executive career at enterprise software leader SAP, including as Chief Operating Officer, China. He earned a bachelor’s degree in Engineering and a master’s in Technology Management at Harbin Institute of Technology, and then an Executive MBA from University of Mannheim Business School. This press release features multimedia. View the full release here: Allen Li has been appointed to the new role of General Manager, China. Image courtesy of Bentley Systems. While Bentley’s infrastructure engineering offerings have become well established in major design institutes and owner organizations, the company is also pursuing substantial growth opportunities as a platform for softwa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom